CMPS COMPASS Pathways
- 7.940
- +0.080+1.02%
- 8.150
- +0.210+2.64%
COMPASS Pathways News
COMPASS Pathways(CMPS.US) 10% Shareholder Sells US$597.96K in Common Stock
$COMPASS Pathways(CMPS.US)$ 10% Shareholder Malievskaia Ekaterina sold 69,461 shares of common stock on Apr 16, 17, 2024 at an average price of $8.6086 for a total value of $597.96K. This transaction
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing
George Jay Goldsmith, 10% Owner, on April 16, 2024, sold 69,461 shares in Compass Pathways (CMPS) for $597,964. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 7,949,07
Express News | Cantor Fitzgerald Reiterates Overweight on Compass Pathways
Atai Life Sciences Upgraded at Maxim on Beckley Investment
COMPASS Pathways(CMPS.US) 10% Shareholder Sells US$461.33K in Common Stock
$COMPASS Pathways(CMPS.US)$ 10% Shareholder Goldsmith George Jay sold 51,500 shares of Common Stock on Apr 1, 2024 at an average price of $8.9579 for a total value of $461.33K. This transaction involv
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing
George Jay Goldsmith, 10% Owner, on April 01, 2024, sold 51,500 shares in Compass Pathways (CMPS) for $461,332. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 8,018,53
Compass Pathways to Participate in Upcoming 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announ
Express News | COMPASS Pathways Shares Are Trading Higher After Morgan Stanley Initiated Coverage on the Stock With an Overweight Rating and Announced a $30 Price Target
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones falling around 250 points on Monday. Shares of Micron Technology, Inc. (NASDAQ:MU) rose sharply during Monday's session after B of A Securities maintained a
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing
George Jay Goldsmith, 10% Owner, on March 28, 2024, sold 51,500 shares in Compass Pathways (CMPS) for $445,552. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 8,070,03
COMPASS Pathways(CMPS.US) 10% Shareholder Sells US$445.55K in Common Stock
$COMPASS Pathways(CMPS.US)$ 10% Shareholder Goldsmith George Jay sold 51,500 shares of Common Stock on Mar 28, 2024 at an average price of $8.6515 for a total value of $445.55K. This transaction invol
The latest information on major US company ratings published on 04/01 (Monday): RIOT, PFC, DOC, TRU, etc.
The latest information on ratings of major US companies was announced on 04/01 (Monday).
Compass Pathways Initiated at Overweight by Morgan Stanley
Compass Pathways Initiated at Overweight by Morgan Stanley
Express News | Morgan Stanley Initiates Coverage On Compass Pathways With Overweight Rating, Announces Price Target of $30
Compass Pathways Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 253.77% Morgan Stanley → $30 Initiates Coverage On → Overweight 03/01/2024 1315.09% HC Wainwrig
Buy Rating on COMPASS Pathways: COMP360's Market Potential and Promising TRD Therapy
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.See previous edition Psychedelics Headlines: Substitution Survey, Fr
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full year 2023.The Numbers:Cash, cash equivalents and short
Compass Pathways Co-Founders Step Down From Board; David Norton Named Interim Chair; Shares Fall
Compass Pathways (CMPS) said Thursday that co-founders George Goldsmith and Ekaterina Malievskaia are stepping down from the board, effective Friday. David Norton. the lead independent director. was n
Analysis
Price Target
No Data
